CYC116 is an orally active small molecule multi-kinase inhibitor with anti-neoplastic activity. CYC116 inhibits Aurora kinases A/B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
Product Specification
| Alternative Name: | 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine |
| |
| Formula: | C18H20N6OS |
| |
| MW: | 368.5 |
| |
| CAS: | 693228-63-6 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | Brown powder. |
| |
| Solubility: | Soluble in DMSO (24mg/ml) or ethanol (1mg/ml). |
| |
| Shipping: | Ambient |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Aurora kinases are known to play a role in mitotic entry, progression and exit. These kinases represent attractive targets for anticancer drug development because they regulate both genomic integrity and cell cycle progression in cancer. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
